Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Meta10-TIL in Advanced Solid Tumors
NCT07106814Phase 1Recruiting
- Sponsor
- The First Affiliated Hospital of USTC
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of metabolically armed tumor-infiltrating lymphocytes in solid tumor (advanced stage), sponsored by The First Affiliated Hospital of USTC. Primary endpoint: Adverse Events at 1 year. Started Aug 2025; status: recruiting.
02
Drugs
metabolically armed tumor-infiltrating lymphocytes
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07106814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07106814.